Galapagos NV (GLPG.AS)
EUR 25.7
(0.78%)
EUR 25.7
(0.78%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 9.59 Million EUR | -56.18% |
| 2022 | 21.9 Million EUR | -18.46% |
| 2021 | 26.85 Million EUR | -8.75% |
| 2020 | 29.43 Million EUR | 15.96% |
| 2019 | 25.38 Million EUR | 0.0% |
| 2018 | - EUR | -100.0% |
| 2017 | 9000.00 EUR | -85.71% |
| 2016 | 63 Thousand EUR | -45.22% |
| 2015 | 115 Thousand EUR | -31.14% |
| 2014 | 167 Thousand EUR | -57.51% |
| 2013 | 393 Thousand EUR | -2.96% |
| 2012 | 405 Thousand EUR | -53.77% |
| 2011 | 876 Thousand EUR | -29.64% |
| 2010 | 1.24 Million EUR | -16.11% |
| 2009 | 1.48 Million EUR | -12.81% |
| 2008 | 1.7 Million EUR | -61.03% |
| 2007 | 4.36 Million EUR | -43.76% |
| 2006 | 7.76 Million EUR | 0.0% |
| 2005 | - EUR | 0.0% |
| 2004 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 7.97 Million EUR | -16.87% |
| 2024 Q3 | 4.22 Million EUR | 5.44% |
| 2024 Q2 | 10.87 Million EUR | 36.3% |
| 2023 Q3 | 14.14 Million EUR | -8.23% |
| 2023 Q2 | 15.41 Million EUR | -3.65% |
| 2023 Q1 | 15.99 Million EUR | -26.95% |
| 2023 FY | 9.59 Million EUR | -56.18% |
| 2023 Q4 | 9.59 Million EUR | -32.17% |
| 2022 FY | 21.9 Million EUR | -18.46% |
| 2022 Q1 | 25.35 Million EUR | -5.6% |
| 2022 Q2 | 24.05 Million EUR | -5.13% |
| 2022 Q4 | 21.9 Million EUR | -3.46% |
| 2022 Q3 | 22.68 Million EUR | -5.69% |
| 2021 Q1 | 28.65 Million EUR | -2.67% |
| 2021 Q2 | 27.9 Million EUR | -2.59% |
| 2021 Q4 | 26.85 Million EUR | 1.78% |
| 2021 Q3 | 26.39 Million EUR | -5.44% |
| 2021 FY | 26.85 Million EUR | -8.75% |
| 2020 Q2 | 27.25 Million EUR | 8.74% |
| 2020 Q3 | 29.06 Million EUR | 6.64% |
| 2020 Q4 | 29.43 Million EUR | 1.27% |
| 2020 FY | 29.43 Million EUR | 15.96% |
| 2020 Q1 | 25.06 Million EUR | -1.25% |
| 2019 Q4 | 25.38 Million EUR | 1.89% |
| 2019 FY | 25.38 Million EUR | 0.0% |
| 2019 Q1 | 24.98 Million EUR | 0.0% |
| 2019 Q3 | 24.91 Million EUR | -2.68% |
| 2019 Q2 | 25.59 Million EUR | 2.44% |
| 2018 Q1 | - EUR | -100.0% |
| 2018 Q3 | - EUR | 0.0% |
| 2018 FY | - EUR | -100.0% |
| 2018 Q4 | - EUR | 0.0% |
| 2018 Q2 | - EUR | 0.0% |
| 2017 FY | 9000.00 EUR | -85.71% |
| 2017 Q4 | 9000.00 EUR | 0.0% |
| 2017 Q3 | - EUR | -100.0% |
| 2017 Q2 | 37 Thousand EUR | -26.0% |
| 2017 Q1 | 50 Thousand EUR | -20.63% |
| 2016 Q4 | 63 Thousand EUR | -17.11% |
| 2016 FY | 63 Thousand EUR | -45.22% |
| 2016 Q1 | 102 Thousand EUR | -11.3% |
| 2016 Q2 | 90 Thousand EUR | -11.76% |
| 2016 Q3 | 76 Thousand EUR | -15.56% |
| 2015 Q1 | - EUR | -100.0% |
| 2015 Q2 | 140 Thousand EUR | 0.0% |
| 2015 FY | 115 Thousand EUR | -31.14% |
| 2015 Q4 | 115 Thousand EUR | -9.45% |
| 2015 Q3 | 127 Thousand EUR | -9.29% |
| 2014 Q4 | 167 Thousand EUR | 0.0% |
| 2014 Q2 | 254 Thousand EUR | 81.43% |
| 2014 Q1 | 140 Thousand EUR | -64.38% |
| 2014 FY | 167 Thousand EUR | -57.51% |
| 2013 FY | 393 Thousand EUR | -2.96% |
| 2013 Q3 | 167 Thousand EUR | -68.37% |
| 2013 Q2 | 528 Thousand EUR | 87.23% |
| 2013 Q4 | 393 Thousand EUR | 135.33% |
| 2013 Q1 | 282 Thousand EUR | -30.37% |
| 2012 Q3 | - EUR | -100.0% |
| 2012 Q4 | 405 Thousand EUR | 0.0% |
| 2012 FY | 405 Thousand EUR | -53.77% |
| 2012 Q2 | 679 Thousand EUR | 0.0% |
| 2011 Q2 | 1.16 Million EUR | 0.0% |
| 2011 FY | 876 Thousand EUR | -29.64% |
| 2011 Q4 | 876 Thousand EUR | 0.0% |
| 2010 Q2 | 1.27 Million EUR | 0.0% |
| 2010 FY | 1.24 Million EUR | -16.11% |
| 2010 Q4 | 1.24 Million EUR | 0.0% |
| 2009 Q2 | 1.75 Million EUR | 0.0% |
| 2009 FY | 1.48 Million EUR | -12.81% |
| 2009 Q4 | 1.48 Million EUR | 0.0% |
| 2008 FY | 1.7 Million EUR | -61.03% |
| 2008 Q4 | 1.7 Million EUR | 0.0% |
| 2007 FY | 4.36 Million EUR | -43.76% |
| 2006 FY | 7.76 Million EUR | 0.0% |
| 2005 FY | - EUR | 0.0% |
| 2004 FY | - EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -183.068% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 82.699% |
| Adocia SA | 13.08 Million EUR | 26.681% |
| Aelis Farma SA | 4.03 Million EUR | -137.642% |
| Biophytis S.A. | 8.27 Million EUR | -16.034% |
| Advicenne S.A. | 17.42 Million EUR | 44.93% |
| genOway Société anonyme | 7.23 Million EUR | -32.662% |
| IntegraGen SA | 1.12 Million EUR | -753.179% |
| Medesis Pharma S.A. | 1.2 Million EUR | -699.667% |
| Neovacs S.A. | 650 Thousand EUR | -1376.308% |
| NFL Biosciences SA | 62.17 Thousand EUR | -15334.104% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -120.268% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -253.205% |
| Sensorion SA | 2.86 Million EUR | -234.497% |
| Theranexus Société Anonyme | 3.64 Million EUR | -163.408% |
| TME Pharma N.V. | 1.16 Million EUR | -722.985% |
| Valbiotis SA | 6.87 Million EUR | -39.517% |
| TheraVet SA | 1.15 Million EUR | -727.336% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -6.646% |
| argenx SE | 18.1 Million EUR | 46.999% |
| BioSenic S.A. | 28.16 Million EUR | 65.925% |
| Celyad Oncology SA | 902 Thousand EUR | -963.858% |
| DBV Technologies S.A. | 13.01 Million USD | 26.29% |
| Genfit S.A. | 70.17 Million EUR | 86.326% |
| GeNeuro SA | 7.73 Million EUR | -24.015% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -81.262% |
| Innate Pharma S.A. | 39.89 Million EUR | 75.946% |
| Inventiva S.A. | 37.4 Million EUR | 74.347% |
| MaaT Pharma SA | 14.07 Million EUR | 31.822% |
| MedinCell S.A. | 58.96 Million EUR | 83.725% |
| Nanobiotix S.A. | 50.56 Million EUR | 81.022% |
| Onward Medical N.V. | 16.87 Million EUR | 43.131% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 29.891% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 79.048% |
| Oxurion NV | 12.33 Million EUR | 22.199% |
| Pharming Group N.V. | 155.29 Million EUR | 93.821% |
| Poxel S.A. | 46.9 Million EUR | 79.539% |
| GenSight Biologics S.A. | 18.42 Million EUR | 47.927% |
| Transgene SA | 1.25 Million EUR | -663.405% |
| Financière de Tubize SA | 79.2 Million EUR | 87.884% |
| UCB SA | 3.03 Billion EUR | 99.684% |
| Valneva SE | 208.81 Million EUR | 95.405% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -25152.632% |